Jim Greenwood discussed the Opioid Crisis with NY Reps. Eliot Engel & Yvette D. Clarke
Jim met with Congresswoman Yvette D. Clarke and Congressman Eliot Engel, both representing districts within New York City, to discuss ways to combat the opioid crisis and the need for increased NIH investment pain treatments and better tools to fight this epidemic.
Left to right: Congresswoman Yvette D. Clarke, Jim Greenwood and Congressman Eliot Engel
Jim Greenwood Leads Fireside Chat with Dr. Rachel Sherman of FDA during the BIO CEO & Investor Conference
Jim led an interesting & engaging day two of the BIO CEO & Investor Conference during a fireside with Dr. Rachel Sherman, Principal Deputy Commissioner of the U.S. Food and Drug Administration.
Left to right: Jim Greenwood, Dr. Rachel Sherman
State, Local, Tribal, and Territorial Ability to Respond to Large-Scale Biological Events: Challenges and Solutions
This meeting of the Study Panel, chaired by former Secretary of Health and Human Services Donna Shalala and former Representative James Greenwood, will provide the Study Panel with a better understanding of the ability of state, local, tribal, and territorial governments to confront infectious disease events and the threat of biological terrorism.
Jim Greenwood cohosted and welcomed the audience at the WuXi Global Forum 2018
Jim joined global healthcare industry visionaries, including Dr. Ruyi He, the Chief Scientist of the Chinese FDA, to cohost and deliver welcoming remarks at the WuXi Global Forum Opening Plenary session. This event has won its reputation as one of the most thought-provoking and forward-thinking events surrounding the JPMorgan Healthcare Conference.
Jim Greenwood participates in panel discussion: "The Future of Biotechnology and Life Sciences Sector - Are we at a Tipping Point?" at the 2018 J.P. Morgan Healthcare Conference (JPM)
Jim joined moderator Sara Radcliffe, President & CEO California Life Sciences and the following panelists to discuss how incredible biopharmaceutical breakthroughs are improving the length and quality of patient lives. The promise of this surge in scientific innovation, however, won’t be fully realized unless it can be matched with innovation in how drug companies bring products to market – with a focus on increasing efficiency and speed while reducing costs.
- Rowan Chapman, Head, Johnson & Johnson Innovation, California
- Ron Cohen, President & CEO, Acorda Therapeutics, Inc.
- Jim Greenwood, President & CEO, Biotechnology Innovation Organization
- Rachel King, CEO, GlycoMimetics, Inc.
- Paul Mignon, President & Global Head, inVentiv Health Selling Solutions, INC Research/inVentiv Health
Jim Greenwood met with MD Senator Van Hollen at GlycoMimetics
Jim traveled up to Rockville, MD today to discuss the value of biotechnology innovation and the importance of federal funding for disease research and development with Senator Van Hollen at GlycoMimetics, a clinical-stage biotechnology company that develops treatments for diseases, especially those with high unmet needs.
Senator Chris Van Hollen (center) and to his left are Rachel King is co-founder and CEO of GlycoMimetics and BIO CEO Jim Greenwood
Jim Greenwood on Bloomberg Radio
While in Boston this week, BIO CEO Jim Greenwood sat down with Bloomberg Boston Bureau Chief Tom Moroney to discuss some of the big issues facing the healthcare industry, including drug pricing, healthcare reform and how biomedical innovation can help solve the opioid crisis. Learn more
Galien Awards Ceremony
BIO CEO Jim Greenwood attended the 11th Annual Prix Galien Awards Ceremony in New York City, recognizing outstanding biomedical and technology achievements that improve the human condition. President Carter won the evening’s top honor for taking critical steps to expand childhood access to immunizations as president and for using his ex-presidency to fight disease and improve public health in communities around the world.
BioNJ CEO Summit
Moderator Michelle Keefe questions BIO CEO Jim Greenwood at the BioNJ CEO Summit about topics ranging from the federal policy landscape to global opportunities for New Jersey biotechs to Greenwood's recent meeting with Governor Chris Christie to discuss how innovation is the key to solving the country's opioid crisis.
SCBIO 2017 ANNUAL CONFERENCE
BIO CEO Jim Greenwood discusses life science industry development with Sam Konduros, President and CEO of SCBIO at the SCBIO 2017 Annual Conference in Charleston. Jim shared insights about federal policy challenges and how South Carolina's growing biotech community can take advantage of global opportunities. South Carolina Gov. Henry McMaster followed Greenwood on stage to outline his commitment to nurture and incentivize life sciences development in the Palmetto State.
Sam Konduros, President and CEO of SCBIO
NMBio Knowledge Fair & Expo
Jim participated in a Keynote & Fireside Chat with Greg Byrnes President & CEO of New Mexico Biotechnology & Biomedical Association, where they two discussed government policy in today’s political landscape and BIO’s ongoing advocacy priorities on behalf of the industry.
Event with Sen. Benjamin Cardin
Jim discussed economic policies in support of Maryland’s life science industry with Senator Ben Cardin (MD-D) and Paragon Bioservices CEO Peter Buzy while touring the University of Maryland BioPark.
Laguna Biotech CEO Forum
Jim participated in a fireside chat with Rick Winningham, Chairman & CEO, Theravance Biopharma, where they two discussed government policy in today’s political landscape and BIO’s ongoing advocacy priorities on behalf of the industy.
I told attendees at the World Orphan Drug Congress in Washington that for patient-centered drug development to really take off, we need the right people at the FDA who can work with biotech companies to make sure the patient voice is incorporated into every aspect of the approval process. It’s equally critical that the FDA has the right staff to manage the breakthrough designation program, so we can speed life-saving cures to patients in need. Congress must reauthorize Prescription Drug User Fee Act (PDUFA VI) by August to forestall devastating layoffs at the FDA.
BIO CEO Jim Greenwood spoke with Maryland Gov. Larry Hogan back stage at the third annual BIO Capitol Region Forum about plans to transform the MD/VA/DC region into a top 3 national hub for biotech by 2023. On the Medimmune campus in Gaithersburg, Md., Greenwood keynoted the conference and then moderated a panel featuring Congressman John Delaney (D-MD) and Dr. Christopher Austin, director of the NIH’s National Center for Advancing Translational Science.
Proud to lead a delegation of U.S. Biotech Company Officials to the 14th BIO Asia International Conference. During our visit, we had the pleasure to meet with Vice Minister Seishi Baba of the Ministry of Health, Labour, and Welfare (MHLW), second from the left. I also gave a keynote address about Japan being an elite biotech hub.
Jim Greenwood delivered testimony to a House Committee on Agriculture, Subcommittee on Commodity Exchanges, Energy and Credit, Hearing: The Next Farm Bill: Rural Development & Energy Programs.
This week Jim Greenwood attended and delivered a presentation at CED Life Science Conference 2017 in Raleigh, NC. Jim's speech highlighted BIO’s ongoing campaign to increase awareness and appreciation for the enormous value delivered by the biopharmaceutical industry and the need to protect the ecosystem that makes new cures and treatments possible.
BIO CEO Jim Greenwood delivered a key message to the Indian government and Prime Minister Damodardas Modi at an economic development conference in Gandhinagar: Successful innovation results not just from scientific and entrepreneurial genius, but also from public policies that reward risk-taking and protect intellectual property. Greenwood asked more than 1,000 political and industry leaders gathered at the Vibrant Gujarat conference: Will India embrace its tremendous potential to innovate or be content to merely imitate? And will India embrace broadly shared global norms on intellectual property rights and welcome the wave of foreign investment, new jobs, international partnerships and M&A that such a decision would bring?
Released “friendly mosquitos” genetically engineered to breed out the invasive species that carries Zika. In a pilot effort in 2 neighborhoods here last year, the release of transgenic mosquitos reduced 133 cases of Dengue to 1. Kudos to Oxitec and Interxion.
Sao Paulo, Brazil
Gave Keynote speech during BIO Latin America. “Biotech companies cannot survive without a healthy ecosystem equally supported by 3 vital groups. I call them the three “ins”— Innovators, investors and institutions.”
Speech at the UK Bioscience Forum, providing perspective on the UK Biotech Sector.
The “Democratic All Star Challenge” charity batting practice event honored the Democratic members of the House Energy and Commerce committee, while it also raised money for the D.C.-based Washington Literacy Center, the Pittsburgh-based Center of Life and Phillies Charities, the charitable arm of the baseball team.
Meeting with Senator Pat Roberts (R-KS), 2016 BIO Legislator of the Year, as part of the 2016 BIO Fly-In Events on Capitol Hill.
Every April 7th from here on out will be Biotechnology Day in the State of California.
This designation was made by the California in a resolution recognizing California as a global leader in life science innovation.
As stated in the resolution, California is home to 2,848 life sciences companies which generate more than $130 billion in revenue and have more than 281,000 employees throughout the state.
April 7th marks the 40th anniversary of Genentech, which is often recognized as the birth of the modern biotechnology industry.
It also is very appropriate that the 2016 BIO International Convention will be returning to the place where this industry got its start – San Francisco this June 6-9. For more information and to register visit convention.bio.org.
The 2015 BIO International Convention, where the global biotech community meets, connecting the people, companies and innovations that help to fulfill the promise of biotechnology through healing, fueling, and feeding the world, concluded today at the Pennsylvania Convention Center. This year’s Convention hosted 29,279 partnering meetings, a new record for the event. Organized by the Biotechnology Innovation Organization (BIO), the event drew 15,858 industry leaders from 69 countries and 47 states, as well as the District of Columbia and Puerto Rico.
I had the honor of meeting with Mr. Yoshihiro Seki, Japan's Parliamentary Vice-Minister of Economy, Trade and Industry (METI), at this week's 12th Annual BIO Asia International Conference and our subsequent Business Development & Policy Delegation to Tokyo. Japan remains the second largest global player in biopharma behind the U.S. Japan's leaders have taken a number of steps toward boosting industry growth and innovation, and industry investors have clearly taken notice.
New York City
Over the course of the last year, Representatives Upton and DeGette, along with their colleagues on the Committee, have solicited feedback from stakeholders across the healthcare ecosystem. They have traveled the country talking to patient groups, public officials, regulators, researchers, industry leaders and investors in an effort to solicit and identify the best possible ideas and proposals.
NORD’s Rare Diseases and Orphan Products Breakthrough Summit is the largest and most meaningful multistakeholder event of its kind – Featuring over 20 speakers from the FDA, over 80 patient organizations and the Pharma/Biotech industry’s foremost experts in orphan product innovation, investment and commercialization. The 2014 Breakthrough Summit is concentrated with innovative content and convenes the top leaders from the FDA, NIH, Industry, Patient Groups, Payers and Research Institutions to address the progress of rare disease diagnosis, genomics, drug development, patient engagement, product approvals, FDA oversight and market accessibility to orphan products.
Durham, North Carolina
BIO President & CEO Jim Greenwood was in North Carolina to tour the Bayer CropScience Bee Care Center and to attend the NCBIO Annual Meeting. In his remarks at the NCBIO meeting, Greenwood provided an update on important developments in Washington, including the 21st Century Cures initiative. He also highlighted a report BIO and Battelle released showing that North Carolina remains a leader in biotechnology growth and job creation. Greenwood spoke about what is needed at both the federal and state level to ensure that innovation and investment can continue to thrive in North Carolina and around the country.
Sioux Falls, South Dakota
“Thanks to the leadership of Governor Daugaard, South Dakota is emerging as a world leader in agriculture biotechnology, especially in the growing field of animal biotechnology,” said Jim Greenwood, President and CEO of BIO. "Under his leadership, support for research and development in the area has yielded scientific advances such as animals engineered to produce human models of disease or produce antibodies and other human health therapies to treat life-threatening diseases. The state is also home to research involving animal health studies, seed technology, bioenergy and biofuels production."
Rio de Janeiro, Brazil
BIO President & CEO Jim Greenwood kicked off the first-ever BIO Latin America Conference in Rio de Janeiro. The event brought together biotechnology leaders, government officials and policy experts from more than a dozen countries and focused on concrete ways to grow and strengthen the biotechnology sector across Latin America and around the globe. The co-host of the event is Biominas Brasil. In his remarks, Greenwood noted that through events like BIO Latin America, “We look to broaden and deepen our ties to this region’s growing biotechnology sector—to share best practices, to build lasting partnerships and to ensure that our industry continues to grow and thrive across the globe.”
New York City
The reality is that no matter how good your science is and no matter how skillful the entrepreneurs involved in running the companies trying to develop these products are…in the absence of a strong policy environment, you simply can’t succeed. That means funding basic research at NIH. It means policies that drive technology transfer from the academic community into start-ups and it means appropriate tax policy. It means supporting and incubating start-up companies and getting them through the valley of death. It means the right regulatory policies at FDA, the protection of intellectual property and adequate reimbursement. All of these policies have to be right to attract investment into our industry.
This year’s BIO International Convention brought to San Diego leaders in industry, government and academia to help further the promise of biotechnology. From our outstanding keynote speakers, to the record number of partnering meetings, the 2014 Convention was a resounding success. This event continues to provide biotech leaders with the opportunity to showcase the best of our industry.
The Convention featured dynamic Keynotes from Sir Richard Branson and Former Secretary of State Hillary Rodham Clinton, over 800 speakers and 160 sessions in 8 educational tracks and 9 specialty forums which addressed the latest business opportunities, breakthroughs in medicine, diagnostics, the environment, energy production, food and agriculture and more. For session highlights and editorial, visit http://www.biotech-now.org/.
Celebrating its 11th anniversary, the annual 2014 BIO World Congress on Industrial Biotechnology hosted over 1,100 attendees – of which 45 percent were from outside the United States. With 19 reporters registered, media publications in attendance included The Economist, The Philadelphia Inquirer, Biofuels Digest, and the Industrial Biotechnology Journal. At this year’s conference, BIO scheduled a record breaking 1,000 partnering meetings through its One-on-One Partnering™ System.
On Tuesday, April 23, 2014, BIO President & CEO Jim Greenwood joined Stephen Ubl, president & CEO of AdvaMed, and Mark Heesen, president emeritus of the National Venture Capital Association, for a lively conversation about the state of the life science industry. The event was hosted by the Tech Council of Maryland and was moderated by Stephen Thau, a partner at Morrison & Foerster, LLP. The discussion focused on a range of key issues, including the importance of effective public policy in protecting and advancing the enterprise of medical innovation. Panelists highlighted the important role that legislation like the JOBS Act and PDUFA V played in the success of the industry. The groups was bullish on the future, but cautioned that key issues such as reimbursement will be critical to the industry’s long-term success. The group also talked about ways to better attract investment to the Mid-Atlantic region and about the opportunities and challenges in international markets.
More than 250 biotechnology industry representatives from over 40 states, representing hundreds of thousands of American workers, participated in hundreds of meetings with Members of the House and Senate during the BIO Legislative Day Fly-In. Participants will discussed issues critical to the biotechnology industry including, adequate reimbursement for vital therapies under Medicare, FDA funding, strengthening the U.S. patent system, and capital formation issues relevant to biotechnology companies.
Senator Stabenow never relented in her effort to reauthorize the Farm Bill. She led the process with a clear vision to combine America’s agricultural productivity with its strengths in manufacturing and cutting-edge technology, which she laid out at the start by launching the “Grow It Here, Make It Here” initiative. That initiative had a simple premise, that if we use homegrown technology to manufacture products from renewable agricultural resources, we can grow our economy and jobs. The final Farm Bill incorporated the initiative, strengthening the energy programs and expanding them to support companies that make biobased products and renewable chemicals, in addition to advanced biofuels. It is exactly the type of comprehensive policy making that supports long-term innovation and job creation.
New York City
The 16th BIO CEO & Investor Conference is off to a great start. This event has truly grown into a must attend for emerging companies and investors. This year, we have more than 1,300 participants, including more than 850 investors. In addition, we have helped to set up more than 1,700 partnering meetings for participants over the course of the conference. Our world-class partnering system, and the opportunity to hear from key industry leaders, is really what sets this conference apart.
United Arab Emirates
Jim Greenwood participated in a panel discussion at the Financial Times/Julphar MENA Biotechnology and Biosimilar Forum in Dubai. The panel focused on the role of biotechnology in transforming healthcare in the MENA region. During the discussion, Greenwood highlighted the key factors that are critical to growing a successful biotechnology and life sciences sector in the Middle East and in markets around the globe. Learn more about the event.
Jim Greenwood attended the 10th Annual BayBio Pantheon Ceremony, where he presented Dr. Stanley N. Cohen with the BayBio Lifetime Achievement DiNA Award for his contributions to making a transformative difference within the life science industry. Read more on BIOtechNOW
New York City
"Biopharmaceutical companies have discovered that some challenges are beyond the capacities of any one of them, or at least they've discovered that through collaboration they can be more efficient, more effective than they could be otherwise," BIO President and CEO Jim Greenwood said at the Partnering for Cures event in New York City.
During an afternoon plenary session at the World Congress on Industrial Biotechnology, Jim Greenwood, Iowa Lt. Gov. Kim Reynolds and Iowa Biotech Association Executive Director Rachel Hurley presented Dr. Jay Keasling with BIO’s George Washington Carver Award for Innovation in Industrial Biotechnology.
Jim Greenwood joined President and CEO of MassBio Bob Coughlin at the Boston Irish Business Awards Breakfast. Coughlin was recognized for his achievements in business while retaining his connection to Ireland. Learn more about the event.
Jim Greenwood met with life science leaders May 1st to update NCBIO members on national life science issues and to listen to members about industry concerns. Learn more about the event.
"It is hard to believe, but this year BIO reaches a significant milestone as we celebrate 20 years of bringing innovation, opportunity and growth to an industry that heals, fuels and feeds the world."
BIO recently announced its selection of Congressman Richard Neal (D-MA) as Legislator of the Year for 2012-2013 during the 2013 BIO Legislative Day Fly-In.
"Congressman Neal's sponsorship, along with Congressman Gerlach, of the High Technology Small Business Research Incentives Act would help emerging companies find new sources of investment. Furthermore, the Congressman's joint work on legislation to address the Vaccine Excise Tax merits particular commendation," said BIO President and CEO Jim Greenwood.
New York City
"For the health care industry our version of sequestration, over the long-term, is IPAB (the Independent Payment Advisory Board) - which we loathe. It was part of the Affordable Care Act, or Obamacare, and it's an unelected group of folks who get to make tough decisions about cutting Medicare. We are bent on repealing it."
Jim Greenwood moderated a panel at the 15th Annual BIO CEO & Investor Conference that featured Joshua Bolten and John Podesta, two former White House Chiefs of Staff who have served in the trenches under President George W. Bush and President Bill Clinton.
BIO President & CEO Jim Greenwood delivered remarks on the Renewable Fuel Standard and participated in a panel session on the Legacy of Bipartisan Support for Renewable Energy at ACORE’s National Renewable Energy Policy Forum, held on Capitol Hill:
“I had the pleasure of speaking at the RETECH 2012 conference in October. I said then it was time for a call to arms for renewable energy. It is still time to raise that cry. In fact, the need is more urgent today."
Jim spoke to a class from the National Defense University Industrial College of the Armed Forces (ICAF) about biotechnology applications and technologies, industry issues and challenges, regulatory framework, industry financing and investor confidence, ethics and public sentiment about the industry, as well as Congressional support for the industry.
BIO President and CEO Jim Greenwood and his daughter Laura attended one of the official Presidential Inaugural Balls at the Walter E. Washington Convention Center in Washington, DC.
“The new landscape for drug pricing and reimbursement in Germany has potentially far-reaching consequences. Introducing a new product in Germany will now require drug trial designs to highlight patient outcomes. The extra time and investment needed to ensure clinical trial design will satisfy both the regulators and the reimbursement authorities add extra burdens to an already complex and costly process. For smaller companies, this could have a significant impact on the ability to secure needed investment. In addition, Germany is a reference country for pricing negotiations in many other countries inside and outside the EU. It is becoming increasingly vital to engage the policy community by demonstrating the social and economic value of biotechnology innovation.”
BIO President and CEO Jim Greenwood was a guest speaker at a dinner celebrating the 75-year presence of BIO member company UCB in the United States.
"Greg Duncan, UCB's President of North America Operations, serves on BIO's Health Section Governing Board. We appreciate his insights and contributions — particularly in the area of developing policy on pricing and reimbursment and on our work to articulate the value of drugs and biologics."
"BIO is invested in the Chinese economy for the long term. BIO Member Companies are exporting more products and technology to China than ever and want to contribute to a strong and positive U.S.-China commercial relationship."
The Texas Lyceum convened its 2012 Public Conference in Houston to address the impact and challenges of healthcare innovation on the health and economic future of Texans. The goal of the conference is to raise the level of awareness regarding public policy such as commercialization and funding of biomedical research, education in the sciences and medicine, challenges faced and lessons learned by the leading entrepreneurs, and state initiatives including the $3B Cancer and Prevention Research Institute of Texas.
"Our children’s future rests upon our ability to shift as fast as possible to renewable energy sources. But we won’t succeed unless we can convince our political leaders that renewables are ready, reliable and competitive."